Why INT2ACT?
INT2ACT is an exciting opportunity to turn innovation in nucleic acid science into meaningful applications for patient care.
I am proud to contribute to this international effort toward smarter and more effective therapies.
Prof. Avi Schroeder is Professor and Head of the Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies at Technion – Israel Institute of Technology in Haifa, Israel.
Prof. Avi Schroeder’s scientific goal is to develop technologies that benefit patients and elucidate fundamental mechanisms of disease pathogenesis. He and his interdisciplinary, international research team are dedicated to advancing personalized medicine by introducing a new class of diagnostic and therapeutic nanotechnologies. His research focuses on targeted drug delivery systems, specifically the study and development of lipid-based micro- and nanotechnologies for the treatment of cancer, neurodegenerative diseases, and osteoarthritis, through the exploration of new materials for nucleic acid and protein delivery. Moreover, his group employs synthetic biology approaches to engineer artificial cells for applications in medicine and food technology.
Besides INT2ACT, Prof. Schroeder participates in the EIC-funded PERSEUS project, which develops novel nanotechnology-based cancer therapies for deep-seated tumors.
I am a chemical engineer with a research interest at the interface of nanotechnology and medicine. My ultimate goal is to establish a significant research operation, train a new generation of scientists, and contribute to the advancement of the scientific, medical and general communities.
I conducted my postdoctoral studies at the Massachusetts Institute of Technology (MIT) with Prof. Robert Langer and Prof. Daniel G. Anderson, and earned my Ph.D. jointly from the Hebrew University and Ben-Gurion University under the supervision of Prof. Chezy Barenholz and Prof. Joseph Kost. In 2012, I joined the Department of Chemical Engineering at the Technion – Israel Institute of Technology, where I am now a tenured Professor leading the Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies.
I am the recipient of more than 30 national and international awards, the author of over 80 scientific papers, the inventor of more than 20 patents, and the co-founder of several startup companies based on my discoveries. I served as President of the Controlled Release Society (2024–2025) and I am an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
Mora-Raimundo, P., Gilon, A., Kadosh, H., Richtman, Y., Sela, M., Ackerman, S., Chen, G., Abel, R., Kagan, S., Sharf-Pauker, N., Gigi, O., Abumanhal-Masarweh, H., Tripathi, U., Saada, M., Shemen, A., Link-Sourani, D., Shklover, J., Farah, R., Horowitz-Kraus, T., Hadjidemetriou, M., Kostarelos, K., Stern, S., Schroeder, A. (2025) Music enhances lipid nanoparticle brain delivery and mRNA transfection in brain cells. Journal of Controlled Release 114301. https://doi.org/10.1016/j.jconrel.2025.114301
Sela, M., Chen, G., Kadosh, H., Kagan, T., Nicola, R., Turutov, S., Richtman, Y., Zhige, L., Albalak Menasherov, M. R., Kagan, S., Schroeder, T., Mora-Raimundo, P., Kablan, R., Egorov, E., Odeh, A., Abu-Raiya, T., Ionita, I., Freilich, I., Kaneti, G., Knani, I., Arav, Y., Leichtmann-Bardoogo, Y., Tadmor, K., Shklover, J., Patriarchi, T., Danino, D., Hasson, P., Ashery, U., Zeisel, A., Maoz, B. M., Laviv, T., Radinsky, K., Schroeder, A. (2025) AI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism. ACS Nano. https://doi.org/10.1021/acsnano.4c15013
Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., Popat, A., Prestidge, C. A., Rijcken, C. J. F., Sarmento, B., Schmid, R. B., Schroeder, A., Subramaniam, S., Thorn, C. R., Whitehead, K. A., Zhao, C.-X., Santos, H. A. (2024) A translational framework to DELIVER nanomedicines to the clinic. Nature Nanotechnology 19(11), 1597–1611. https://doi.org/10.1038/s41565-024-01754-7
Sela, M., Poley, M., Mora-Raimundo, P., Kagan, S., Avital, A., Kaduri, M., Chen, G., Adir, O., Rozencweig, A., Weiss, Y., Sade, O., Leichtmann-Bardoogo, Y., Simchi, L., Aga-Mizrachi, S., Bell, B., Yeretz-Peretz, Y., Zaid Or, A., Choudhary, A., Rosh, I., Cordeiro, D., Cohen-Adiv, S., Berdichevsky, Y., Odeh, A., Shklover, J., Shainsky-Roitman, J., Schroeder, J. E., Hershkovitz, D., Hasson, P., Ashkenazi, A., Stern, S., Laviv, T., Ben-Zvi, A., Avital, A., Ashery, U., Maoz, B. M., Schroeder, A. (2023) Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson’s disease. Advanced Materials 35(51), 2304654. https://doi.org/10.1002/adma.202304654
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., Shi, J., Schroeder, A., Conde, J. (2022) Nanodelivery of nucleic acids. Nature Reviews Methods Primers 2(1), 24. https://doi.org/10.1038/s43586-022-00104-y